Follow us on:

Linkedin Facebook

EDX Medical publishes Annual Report and Notice of AGM

EDX Medical Group plc

EDX Medical Group Plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced that its annual general meeting (AGM) will be held at Mezzanine Room, 1 Wimpole Street, Westminster, London, W1G 0AE on 30 September 2024 at 2:00 p.m.

The annual report and financial statements for the year ended 31 March 2024, Notice of AGM and Form of Proxy will be posted today, 4 September 2024, to eligible shareholders.

31Mar24-EDX-Medical-Group-plc-ARA-finalDownload

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

EDX Medical Group plc

EDX Medical and Spire Healthcare sign MOU for diagnostic partnership

EDX Medical Group has partnered with Spire Healthcare to enhance digital diagnostics for cancer and other diseases, promising innovative patient care and improved outcomes.
EDX Medical Group plc

EDX Medical Group to launch highly accurate early detection test for testicular cancer

EDX Medical Group is set to launch TC100, a groundbreaking early detection test for testicular cancer in the UK, offering unparalleled accuracy for improved patient care.
EDX Medical Group plc

EDX Medical Group raises £3.0 million to accelerate its prostate cancer ‘super test’

EDX Medical Group plc has secured £3 million by issuing 21.4 million new shares at 14p each, boosting its innovative prostate cancer diagnostic efforts.
EDX Medical Group plc

EDX Medical Group signs master service agreement with The Royal Marsden

EDX Medical Group has secured a three-year master service agreement with The Royal Marsden NHS Foundation Trust to provide innovative diagnostic solutions for cancer care.
EDX Medical Group plc

EDX Medical develops new ‘super test’ for prostate cancer

EDX Medical Group plc unveils a revolutionary AI-driven prostate cancer 'super test,' offering high accuracy and personalised treatment insights.
EDX Medical Group plc

EDX Medical strengthens shareholder value by cancelling legacy warrants

EDX Medical Group (LON:EDX) cancels 5.37 million warrants, enhancing stability and reducing potential dilution for shareholders amidst robust growth.

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple